Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Pulmonary Obstructive Disorder (COPD): Update Bulletin #3 [January 2019]

Product Code:
596201010
Publication Date:
January 2019
Format:
PDF
Price:
$1,315

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the COPD market. Within this update, KOLs provided their views on the following key events: GlaxoSmithKline and Innoviva announcing that the EC has authorised an expanded label for once-daily Trelegy Ellipta; the EMA’s CHMP adopting a positive opinion recommending a label change for Chiesi’s Trimbow, already approved for the treatment of COPD; and AstraZeneca announcing that the EC has approved Bevespi Aerosphere in a pressurised metered-dose inhaler as a maintenance treatment for COPD.

Business Questions:

• How do KOLs view the IMPACT study data for Trelegy Ellipta in COPD?
• What impact do KOLs expect from the label extension for Trelegy Ellipta and how will it influence physician prescribing behaviour?
• Do experts have any cost concerns with Trelegy Ellipta?
• How do KOLs see Chiesi’s Trimbow in relation to GSK’s Trelegy Ellipta?
• Which factors influence physician prescribing behaviour for fixed triple combinations?
• Will Trimbow’s label expansion help it to compete more effectively in the market?
• On what basis are physicians selecting patients to be prescribed the triple therapy?
• How do experts view the pMDI inhaler device for Bevespi Aerosphere?
• How do KOLs view the uptake of Bevespi Aerosphere in the main markets?
• To compete effectively what do KOLs suggest AstraZeneca will need to do in this segment and why?





customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved